Neuroene Therapeutics offers novel small molecule mitochondrial therapeutics for epilepsy, Parkinson's Disease, and mitochondrial disease.
Neuroene Therapeutics has raised $400K in total funding. The most recent round was Grant. The last funding was announced in June 2024.
Neuroene Therapeutics's investors include Johnson & Johnson Innovation, National Institutes of Health, National Institute of Neurological Disorders and Stroke, Small Business Innovation Research.
Neuroene Therapeutics is headquartered in Kensington, United States.
Neuroene Therapeutics offers novel small molecule mitochondrial therapeutics for epilepsy, Parkinson's Disease, and mitochondrial disease.
Neuroene Therapeutics is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Neuroene Therapeutics — Funding & Investors." VCBacked, June 2, 2024, https://www.vcbacked.co/company/neuroene-therapeutics. Accessed July 19, 2026.
VCBacked. (2024). Neuroene Therapeutics — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/neuroene-therapeutics
{{cite web |title=Neuroene Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/neuroene-therapeutics |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated